Manitoba
Health and Seniors Care

Information for Pharmacists

UPDATED - Claims Submission Procedure – Methadone

Effective August 5, 2021

Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.

- The Claims Submission Procedure - Methadone, which first came into effect on October 16, 2014:
  - enhances patient safety by ensuring a more consistent and clear indication in the patient's DPIN history of the dose of methadone prescribed for and dispensed to the patient; and
  - ensures a consistent process for adjudication and reimbursement of methadone preparations by Manitoba through DPIN.

- **NONE of the methadone, Methadose and/or Metadol-D 10 mg/ml Concentrate products are interchangeable with one another. Health Canada issued a safety alert in July 2020 advising that that there may be a link between switching methadone-containing products used to treat opioid use disorder and the risk of lack of effect, which may present as withdrawal symptoms, which can lead to serious harms.** Pharmacists should refer to The College of Pharmacists of Manitoba (CPhM) for further information.

Methadone for Opioid Use Disorder:

- "Methadone powder in preparation of an oral solution", PIN 909190, was delisted on October 22, 2015.

- Effective August 5, 2021, the following methadone products will be listed as unrestricted Part 1 benefits:

Drug	DIN
JAMP methadone (sugar free) 10 mg/ml oral concentrate	02495783
ODAN methadone (cherry flavored) 10 mg/ml oral concentrate	02495872
ODAN methadone (sugar free, unflavored) 10 mg/ml oral concentrate	02495880
SANDOZ methadone (sugar free, cherry flavored) 10 mg/ml oral concentrate	02481979

Effective August 5, 2021, Methadose* and Metadol-D** 10 mg/ml Oral Concentrate will be listed as Part 2 benefits:

Drug	DIN
Methadose* 10 mg/ml oral liquid Methadose* Sugar Free 10mg/ml oral liquid <u>Part 2 prescribing criteria:</u> *For treatment of patients who* *(a) are being treated with Methadose, or* *(b) have previously been treated with two or more methadone products listed under Part 1.*	02394596 02394618
Metadol-D** 10 mg/ml oral concentrate <u>Part 2 prescribing criteria:</u> *For treatment of patients who* *(a) are being treated with Metadol-D, or* *(b) have previously been treated with two or more methadone products listed under Part 1.*	02244290

- Pharmacy operators must indicate the quantity of methadone dispensed as the total number of milliliters (ml) of methadone, Methadose*, or Metadol-D** dispensed.

- Pharmacy operators must specify in DPIN the total days' supply of methadone, Methadose*, or Metadol-D** provided to the patient.

- If a patient is dispensed methadone, Methadose*, or Metadol-D** carries, the <u>total</u> quantity of methadone, Methadose*, or Metadol-D** received by the patient must be entered into DPIN along with the correct days' supply. There should be a single entry into DPIN, and not separate entries on the same day.

<u>For example</u>: A prescription is presented for methadone 2240 mg to be dispensed as 80 mg OD for 28 days.

<u>This can be entered as daily or weekly:</u>

Daily	Weekly
Quantity Dispensed: 8 ml	Quantity dispensed: 56 ml
Days' Supply: 1	Days' Supply: 7

- Pharmacy operators will be reimbursed the ingredient cost plus professional fee.

- Pharmacy operators must record and keep a copy of the documentation in a retrievable manner, indicating how all calculations/billings were done, and tracking of all dosages dispensed.

- Methadone compounded into a capsule formulation is not a benefit through Manitoba.

Methadone for Pain Management:

- Metadol*** tablets are considered as a Part 3 benefit for the management of severe cancer related or chronic non-malignant pain that is not well controlled by short and long-acting morphine and hydromorphone as well as fentanyl products, and for use as a replacement for other narcotic analgesics in palliative care patients who are requiring frequent and continuous dosing of short-acting opiates.

Drug	DIN
Metadol*** 1mg tablet	02247698
Metadol*** 5mg tablet	02247699
Metadol*** 10mg tablet	02247700
Metadol*** 25mg tablet	02247701

- Manitoba may conduct audits of the accounts and records of the pharmacy owner relating to methadone claims submitted by the pharmacy owner, to determine compliance with the terms and conditions of this procedure.

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs posted at:
https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html

Please send an e-mail to PDPInfoAudit@gov.mb.ca.